Volition, a multi-national company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers.

**Early Diagnosis is Key**

As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

**Financial Snapshot (as of 30th September 2016)**

Ticker: NYSE MKT: VNRX  
Sector: Healthcare: Diagnostics & Research  
Market Cap: $125m  
52 week range: $3.05-$5.86  
Stock Price: $5.30  
Cash-on-hand: $12.5m*  

* this figure excludes gross proceeds from an October 2016 equity offering totaling $12.4 million.

**Rethinking the Approach to Cancer**

“Current cancer diagnosis frequently involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q™ technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing”  
*Dr Jake Micallef, Chief Scientific Officer*

Nu.Q™ represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis. **A simple test, just a drop of blood.**

Nu.Q’s™ unique technology looks for very early ‘nucleosomic’ markers of cancer. Nu.Q™ uses an array of simple, cost-effective, and accurate blood tests. These tests may identify early stage cells before the cancer spreads; providing medical professionals increased diagnostic power. Nu.Q™ can potentially reduce the strain on over-burdened healthcare systems.

**How it Works**

Cancer leads to irregular levels of uniquely structured nucleosomes in the blood. A nucleosome is a section of DNA wrapped around a core of proteins. Through a simple test, with less than a drop of blood, we are able to detect those unique nucleosomes; and by measuring and analyzing them, our Nu.Q™ tests can establish whether cancer is present in the patient.

**Empowering Reassurance**

volitionrx.com
Volition’s initial Nu.Q™ products are focusing on colorectal cancer. Colorectal cancer is responsible for over 200,000 deaths in Europe each year, almost 50,000 deaths in the USA and nearly 700,000 deaths worldwide.

- The Nu.Q™ Colorectal Cancer Screening Triage Test is CE Marked and available for use in the EU Market.
- This innovative test has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer. There is a significant lack of capacity within healthcare systems, which means many countries are struggling to meet colonoscopy demand; not only for screening but also diagnosis. Therefore, Nu.Q™ can offer healthcare systems the opportunity to streamline demand, enabling clinicians to focus on those patients most at risk.

Products in Development

Colorectal Cancer
- Interim results of a panel of 4 Nu.Q™ assays detected 81% of colorectal cancers at 78% specificity (vs. Healthy) in a cohort of 4,800 symptomatic patients.
- A panel of 4 normalised Nu.Q™ assays detected 67% of high risk adenomas at 80% specificity in a cohort of 530 symptomatic patients.

Pancreatic Cancer
There is a clear medical need for a reliable, simple, and accurate diagnostic test for pancreatic cancer. Currently, emergency presentation is the most common route to diagnosis, and only 21% of patients survive for more than a year.

- A panel of 4 Nu.Q™ assays plus CA19-9 in a pilot study of 59 patients detected 92% of pancreatic cancers at 100% specificity.
- Interim results of a panel of 2 Nu.Q™ assays plus CEA detected 95% of pancreatic cancers at 84% specificity.

Lung Cancer
Lung cancer is the most common cancer worldwide. Only 10% of lung cancer patients will survive for five years or more. Current screening methods for lung cancer are widely regarded as too inaccurate and expensive for widespread use.

- A panel of 4 Nu.Q™ assays in a pilot study of 73 patients detected 93% of lung cancers at 91% specificity.

Ongoing Clinical Trials

<table>
<thead>
<tr>
<th>Institution</th>
<th>Condition</th>
<th>Sample Collection</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer</td>
<td>Retrospective</td>
<td>4,800 symptomatic</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer</td>
<td>Prospective</td>
<td>14,000 screening population</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal cancer and other cancers</td>
<td>Prospective, longitudinal</td>
<td>30,000 screening population to provide 3 samples (90,000 samples total)</td>
</tr>
<tr>
<td>University of Bonn</td>
<td>27 most prevalent cancers</td>
<td>Prospective</td>
<td>4,700</td>
</tr>
<tr>
<td>German Cancer Research Center (DKFZ)</td>
<td>Pancreatic</td>
<td>Retrospective</td>
<td>750</td>
</tr>
</tbody>
</table>

Our Expert Team
Volition was established in 2010 when our team saw a chance to bring together the long-established ELISA diagnostic technology with cutting-edge nucleosome detection and analysis techniques. We have grown over the years and are now a collective force of distinct individuals with a single aim – to save lives by revolutionizing the way cancer is diagnosed.

Cameron Reynolds MBA
President & Chief Executive Officer

Jake Micallef PhD MBA
Chief Scientific Officer

Jason Terrell MD
Chief Medical Officer & Head of US Operations

Jasmine Kway PhD
Vice President of Asia

Louise Day
Chief Marketing & Communications Officer

Gaetan Michel PhD
Chief Executive Officer, Belgium Volition

David Kratochvil MBA
Chief Financial Officer & Treasurer

Rod Rootsaeart LLB
Corporate Secretary